Canada · Delayed Price · Currency is CAD BioSyent Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw record revenue of CAD 13.9 million, driven by the Oral Science acquisition, which was immediately accretive. Adjusted EBITDA and net income grew 22% and 20% year-over-year, respectively, with strong cash generation and continued shareholder returns.
Fiscal Year 2025
-
Revenue grew 23% to over CAD 43 million in 2025, with net income up 24% and strong margins. The Oral Science acquisition diversifies revenue and adds a new oral health platform, while capital allocation remains focused on growth, dividends, and buybacks.
-
Record Q3 and YTD results with double-digit revenue and profit growth, strong margins, and continued cash returns to shareholders. Key brands performed well, with FeraMAX maintaining market leadership and new assets in the pipeline.
-
Q2 2025 revenue grew 14% year-over-year to over $10 million, with strong EBITDA and NIAT margins. All business segments contributed to growth, and the company maintained a robust balance sheet, increased dividends, and continued share buybacks.
-
Record Q1 2025 with revenue up 42% and EBITDA up 45% year-over-year. Net income margin reached 21%, and the company maintained a strong cash position with no debt, while continuing to invest in growth and return capital to shareholders.
-
Strong financial performance and consistent profitability underpin a strategy focused on product innovation, disciplined capital deployment, and portfolio diversification. Recent acquisitions and launches are expected to drive future growth, with at least two new products planned.
Fiscal Year 2024
-
Achieved record Q4 and full-year revenue growth, with strong EBITDA and EPS increases. Portfolio diversification, including the Tibelia Global acquisition and new product launches, positions the business for continued double-digit growth, while capital returns to shareholders remain robust.
-
Record quarterly sales were achieved, led by Canadian pharmaceuticals, while international sales declined but are expected to recover. EPS rose to CAD 0.60 on a trailing 12-month basis, and the company remains debt-free with a strong cash position.
-
The company reported sustained profitability, strong revenue growth, and a robust balance sheet, driven by a focus on unique pharmaceutical products and strategic acquisitions. Recent highlights include the Tibella acquisition, new product launches, and increased dividends, with growth expected from both existing and upcoming assets.
-
Q2 and H1 2024 saw record revenues, strong EBITDA and net income growth, and continued profitability. Key brands performed well, new products and innovations drove diversification, and capital was returned to shareholders through buybacks and dividends.